RYBREVANT FASPRO
Live / Applied — Second extension granted (statement of use) (as of 15 Dec 2025)
What this means for you
Not registered yet, but its 12 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98597886
- Mark type
- Stylized text
- Filed
- 12 Jul 2024
- Published for opposition
- 26 Nov 2024
- Attorney of record
- Cheryl L. Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of oncological diseases and disorders
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 03 Feb 2026 — TEAS STATEMENT OF USE RECEIVED
- 16 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Dec 2025 — SOU EXTENSION 2 GRANTED
- 15 Dec 2025 — SOU EXTENSION 2 FILED
- 15 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 May 2025 — SOU EXTENSION 1 GRANTED
- 30 May 2025 — SOU EXTENSION 1 FILED
- 30 May 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Nov 2024 — PUBLISHED FOR OPPOSITION
- 20 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 29 Oct 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Oct 2024 — ASSIGNED TO EXAMINER